1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Karrison TG, Ferguson DJ and Meier P:
Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst.
91:80–85. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Coleman RE: Skeletal complications of
malignancy. Cancer. 80 (8 Suppl):S1588–S1594. 1997. View Article : Google Scholar
|
4
|
Ahn SG, Lee HM, Cho SH, Lee SA, Hwang SH,
Jeong J and Lee HD: Prognostic factors for patients with bone-only
metastasis in breast cancer. Yonsei Med J. 54:1168–1177. 2013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Jacobson AF, Shapiro CL, Van den Abbeele
AD and Kaplan WD: Prognostic significance of the number of bone
scan abnormalities at the time of initial bone metastatic
recurrence in breast carcinoma. Cancer. 91:17–24. 2001. View Article : Google Scholar : PubMed/NCBI
|
6
|
Gobbini E, Ezzalfani M, Dieras V, Bachelot
T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A,
Dalenc F, et al: Time trends of overall survival among metastatic
breast cancer patients in the real-life ESME cohort. Eur J Cancer.
96:17–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
7
|
Briasoulis E, Karavasilis V, Kostadima L,
Ignatiadis M, Fountzilas G and Pavlidis N: Metastatic breast
carcinoma confined to bone: Portrait of a clinical entity. Cancer.
101:1524–1528. 2014. View Article : Google Scholar
|
8
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bundred NJ, Walker RA, Ratcliffe WA,
Warwick J, Morrison JM and Ratcliffe JG: Parathyroid hormone
related protein and skeletal morbidity in breast cancer. Eur J
Cancer. 28:690–692. 1992. View Article : Google Scholar : PubMed/NCBI
|
10
|
Vargas SJ, Gillespie MT, Powell GJ,
Southby J, Danks JA, Moseley JM and Martin TJ: Localisation of
parathyroid hormone-related protein mRNA expression in breast
cancer and metastatic lesions by in situ hybridisation. J Bone
Miner Res. 7:971–979. 1992. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kang Y, Siegel PM, Shu W, Drobnjak M,
Kakonen SM, Cordón-Cardo C, Guise TA and Massagué J: A multigenic
program mediating breast cancer metastasis to bone. Cancer Cell.
3:537–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Geisler J, Lønning PE, Krag LE, Løkkevik
E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE,
et al: Changes in bone and lipid metabolism in postmenopausal women
with early breast cancer after terminating 2-year treatment with
exemestane: A randomised, placebo-controlled study. Eur J Cancer.
42:2968–2975. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Perez EA, Josse RG, Pritchard KI, Ingle
JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ,
Shepherd LE, et al: Effect of letrozole versus placebo on bone
mineral density in women with primary breast cancer completing 5 or
more years of adjuvant tamoxifen: A companion study to NCIC CTGMA.
17. J Clin Oncol. 24:3629–3635. 2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Paget S: The distribution of secondary
growths in cancer of the breast. Cancer Metastasis Rev. 8:98–101.
1889.
|
15
|
Chin AR and Wang SE: Cancer tills the
premetastatic field: Mechanistic basis and clinical implications.
Clin Cancer Res. 22:3725–3733. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Liu Y and Cao X: Characteristics and
significance of the pre-metastatic niche. Cancer Cell. 30:668–681.
2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Lipton A, Chapman JW, Leitzel K, Garg A,
Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M,
et al: Osteoporosis therapy and outcomes for postmenopausal
patients with hormone receptor-positive breast cancer: NCIC CTG
MA.27. Cancer. 123:2444–2451. 2017. View Article : Google Scholar : PubMed/NCBI
|
18
|
Gnant M, Mlineritsch B, Stoeger H,
Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M,
Hubalek M, Pristauz G, et al: Adjuvant endocrine therapy plus
zoledronic acid in premenopausal women with early-stage breast
cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol. 12:631–641. 2011. View Article : Google Scholar : PubMed/NCBI
|
19
|
Gnant M, Mlineritsch B, Luschin-Ebengreuth
G, Stoeger H, Dubsky P, Jakesz R, Singer C, Eidtmann H, Fesl C,
Eiermann W, et al: Long-term follow-up in ABCSG-12: Significantly
improved overall survival with adjuvant zoledronic acid in
premenopausal patients with endocrine-receptor-positive early
breast cancer. Cancer Res. 71 (3 Suppl):S1–S2. 2011. View Article : Google Scholar
|
20
|
Coleman RE, Marshall H, Cameron D, Stoeger
H, Dubsky P, Jakesz R, Singer C, Fest C, Eiermann W, Marth C, et
al: Breast cancer adjuvant therapy with zoledronic acid. N Engl J
Med. 365:1396–1405. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du
Y, Shao Z and Lu J: The efficacy of zoledronic acid in breast
cancer adjuvant therapy: A meta-analysis of randomised controlled
trials. Eur J Cancer. 48:187–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Gnant M, Pfeile Gr, Dubsky PC, Hubalek M,
Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, et
al: Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre,
randomised, double-blind, placebo-controlled trial. Lancet.
386:433–443. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Coleman RE, Smith P and Rubens RD:
Clinical course and prognostic factors following bone recurrence
from breast cancer. Br J Cancer. 77:336–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
24
|
Cleeland CS, Body JJ, Stopeck A, von Moos
R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K,
Masuda N, et al: Pain outcomes in patients with advanced breast
cancer and bone metastases: Results from a randomized, double-blind
study of denosumab and zoledronic acid. Cancer. 119:832–838. 2013.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Stopeck AT, Lipton A, Body JJ, Steger GG,
Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA,
Viniegra M, et al: Denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast
cancer: A randomized, double-blind study. J ClinOncol.
28:5132–5139. 2010. View Article : Google Scholar
|
26
|
Steger GG and Bartsch R: Denosumab for the
treatment of bone metastases in breast cancer: Evidence and
opinion. Ther Adv Med Oncol. 3:233–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Parmelee PA, Thuras PD, Katz IR and Lawton
MP: Validation of the cumulative illness rating scale in a
geriatric residential population. J Am Geriatr Soc. 43:130–137.
1995. View Article : Google Scholar : PubMed/NCBI
|
28
|
Van Poznak CH, Temin S, Yee GC, Janjan NA,
Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE,
Theriault RL, et al: American Society of Clinical Oncology
executive summary of the clinical practice guideline update on the
role of bone-modifying agents in metastatic breast cancer. J
ClinOncol. 29:1221–1227. 2011. View Article : Google Scholar
|
29
|
Tesarova P: Breast cancer in the
elderly-Should it be treated differently? Rep Pract Oncol
Radiother. 18:26–33. 2013. View Article : Google Scholar
|
30
|
Kaplan EL and Meier P: Nonparametric
estimation of incomplete observations. J Am Stat Assoc. 53:457–481.
1958. View Article : Google Scholar
|
31
|
Schemper M and Smith TL: A note on
quantifying follow-up in studies of failure time. Control Clin
Trials. 17:343–346. 1997. View Article : Google Scholar
|
32
|
Fisher RA: On the interpretation of
χ2 from contingency tables and the calculation of P. J
Royal Stat Soc. 85:87–94. 1922. View
Article : Google Scholar
|
33
|
Mantel N: Chi-square tests with one degree
of freedom: Extensions of the Mendel-Haenszel procedure. J Am Stat
Assoc. 58:690–700. 1963. View Article : Google Scholar
|
34
|
Peto R and Peto J: Asymptomatically
efficient rank invariant test procedures. J R Stat Soc A.
135:185–206. 1972. View Article : Google Scholar
|
35
|
Cox DR: Regression models and life tables
(with discussion). J Royal Stat Soc (Series B). 74:187–200.
1972.
|
36
|
Falk S and Dickenson AH: Pain and
nociception: Mechanisms of cancer-induced bone pain. J Clin Oncol.
32:1647–1654. 2014. View Article : Google Scholar : PubMed/NCBI
|
37
|
Julius D and Basbaum AI: Molecular
mechanisms of nociception. Nature. 413:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
38
|
Ignatov A, Eggemann H, Burger E and
Ignatov T: Patterns of breast cancer relapse in accordance to
biological subtype. J Cancer Res Clin Oncol. 144:1347–1355. 2018.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Sherry MM, Greco FA, Johnson DH and
Hainsworth JD: Metastatic breast cancer confined to the skeletal
system. An indolent disease. Am J Med. 81:381–386. 1986. View Article : Google Scholar : PubMed/NCBI
|
40
|
Leone BA, Romero A, Rabinovich MG, Vallejo
CT, Bianco A, Perez JE, Machiavelli M, Rodriguez R and Alvarez LA:
Stage IV breast cancer: Clinical course and survival of patients
with osseous versus extraosseous metastases at initial diagnosis.
The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J
Clin Oncol. 11:618–622. 1988. View Article : Google Scholar : PubMed/NCBI
|
41
|
Perez JE, Machiavelli M, Leone BA, Romero
A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Cuevas MA and
Alvarez LA: Bone-only versus visceral-only metastatic pattern in
breast cancer: Analysis of 150 patients. A GOCS study. Grupo
Oncológico Cooperativo del Sur. Am J Clin Oncol. 13:294–298. 1990.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Parkes A, Clifton K, Al-Awadhi A, Oke O,
Warneke CL, Litton JK and Hortobagyi GN: Characterization of bone
only metastasis patients with respect to tumor subtypes. NPJ Breast
Cancer. 4:22018. View Article : Google Scholar : PubMed/NCBI
|
43
|
Niikura N, Liu J, Hayashi N, Palla SL,
Tokuda Y, Hortobagyi GN, Ueno NT and Theriault RL: Treatment
outcome and prognostic factors for patients with bone-only
metastases of breast cancer: A single-institution retrospective
analysis. Oncologist. 16:155–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
44
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|